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INTRODUCTION
Although living donor LT (LDLT) has now become an option
for treating patients with end-stage liver disease, its application
may still be limited by the need for an appropriate living donor
(1, 2). Under these circumstances, ABO incompatible (ABOi) LDLT
has been practiced in Japan with recently improved outcomes by
the recent invention and application of rituximab, a novel anti -
CD20 antibody terminating B-lymphocytes (3).
In applying rituximab in LDLT, however, it needs to be admin-
istered at least a few weeks before LDLT for its desirable effects.
It is attributed that rituximab rituximab can only terminate CD-20
positive B-lymphocytes and it takes at least a few weeks to CD-
20 negative plasma cells to disappear spontaneously (4, 5). Thus,
the application of ABOi-LDLT in emergent situation including acute
liver failure (ALF) has not been a suitable option. In order to over-
come this issue, we reported that high dose intravenous immuno-
globulin (IVIG) was effective for treating antibody-mediated rejec-
tion (AMR) caused by remnant plasma cells after administration of
rituximab (5). Progression of hepatic coma is the most significant
determining prognostic factor in ALF, and therefore we recently
started to use high-flow continuous hemodiafiltration (HF-CHDF)
to treat hepatic coma and wait ABOi-LDLT for days to weeks after
administration of rituximab (6).
In this article, we describe the historical changes in treatment
strategies in applying ABOi-LDLT for ALF as a single institute ex-
periences.
MATERIALS AND METHODS
Patients
Between May 1997 and December 2014, 486 LDLTs in adults in-
cluding 30 LDLTs using ABOi grafts were performed at Kyushu
University Hospital, Japan. Among them, 5 patients received ABOi
LDLT for acute liver failure (Table 1). All the LDLTs were per-
formed after obtaining full informed consent from all patients and
approval by the Liver Transplantation Committee of Kyushu Uni-
versity. The basic surgical procedures and techniques were de-
scribed previously (1, 7, 8). All 5 patients received duct- to-duct
biliary reconstruction. The mean follow-up period was 3.83.7
years.
Basic immunosuppression
The basic immunosuppression induction regimen in ABOi LDLT
involved the administration of tacrolimus (Tac) with mycopheno-
late mofetil (MMF) and steroids (Table 2). Currently, MMF is
started 7 days before LDLT at a dose of 2 g/day, and increased to
3 g/day after LDLT, then decreased to 2 g/day once the blood cal-
cineurin inhibitor level reaches an appropriate level. Tac is started
within 3 days after LDLT once the kidney function has recovered.
The target Tac level ranges between 12 to 15 ng/ml for the first
post-LDLT month and is titrated down to 8 to 10 ng/ml for the
next few months. When patients experience Tac associated com-
plications, especially encephalopathy, Tac is converted to Cy-
closporine A (CsA). The target CsA level ranges from 200 to 250
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ng/ml for the first post-LDLT month and was titrated down to 100
to 150 ng/ml for the next few months. A gram of methylpredniso-
lone is given after reperfusion, and tapered from 200 mg to 40 mg
over 10 days, then switched to 20 mg of oral Prednisolone and ta-
pered off in 6 months after the LDLT.
Plasma exchange (PE) was performed to lower the isoagglutinin
titer64-128. Splenectomy was performed during LDLT.
Local infusion
Local infusion via the portal vein or hepatic artery was used for
between 2001 and 2006 (Table 2). A 16 G double lumen catheter
was introduced from the umbilical vein or the mesenteric vein for
portal vein orgastroduodenal artery for hepatic artery. Protease in-
hibitor (nafamostat mesilate, 200 mg/day), Prostaglandin E1 (500
mcg/day) and methylprednisolone (50 mg/day) were given for 14
days after LDLT.
Rituximab
Rituximab (500 mg/body) was given has been administered
since the Case #2 in 2005. As soon as the indication of the recipi-
ent with ALF was confirmed and the donor evaluation including
volumetry and hematological/serological tests were completed,
rituximab was administered. PE was held at least 8 hours after
administration of rituximab and the number of CD-20 positive lym-
phocytes were evaluated.
High-flow continuous hemodiafiltration (HF-CHDF)
HF-CHDF was performed as continuous venovenous hemodiafil-
tration to treat patients with marked comorbidities and general
hemodynamic instability. Vascular access was created in the inter-
nal jugular vein or the femoral vein, using a 12-Fr flexible triple -
lumen catheter (Blood access catheterTM, Arrow International Inc.,
Reading, PA, USA). A PMMA membrane hemofilter (Hemofeel
CHTM, Toray Medical Co. Ltd., Tokyo, Japan) was placed in the cir-
cuit. Nafamostat mesilate (FuthanTM, Torii Pharmaceutical Co. Ltd.,
Tokyo, Japan) was used as anticoagulant, with the dose adjusted to
maintain an activated coagulation time of 150-200 seconds. The
operating conditions were set as follows : blood flow rate, 150-200
ml/min ; dialysate flow rate, 8 -20 L/hr ; and filtration rate, 1.0 -2.0
L/hr. The hemodiafiltration system was continuously monitored
with a personal bedside console (JUN-500TM, Ube Medical Co.
Ltd., Tokyo, Japan).
Values
The values are expressed as the meanstandard deviation.
RESULTS
Recipient and donor data
The five recipients who received ABOi-LDLT for ALF included
all females, and the mean age was 44.619.3 years. The etiologies
for ALF included autoimmune hepatitis in three and unknown
cause. The mean model for end-stage liver disease score was
23.47.7.
The donors included four males and one female, and the mean
age, graft volume and graft volume/standard liver volume were,
38.69.1 years, 51491 g, and 46.410.4%, respectively (Table 1).
Immunomodulation for ABOi-LDLT
The desensitization protocol for ABOi barrier included Case #1 ;
local infusion (portal vein)+plasma exchange (PE), Case #2 ; local
infusion (hepatic artery)+rituximab+PE, Case #3 and #4 ; rituxi-
mab+PE, and Case #5 ; rituximab+PE under high-flow continuous
hemodiafiltration.
When Case #1 was performed, rituximab was not available,
and therefore local infusion of steroids, protease inhibitor and
prostaglandin, under the control of isoagglutinin titer by PE was
performed. Although isoagglutinin titer was controlled without ap-
plying PE after LDLT, the patient started to have diffuse thrombo-
sis in the intrahepatic portal system 2 weeks after LDLT, resulting
in graft necrosis and death. Although the definite reason for the
diffuse portal thrombosis is unclear, we speculate that abrupt dis-
continuation of intra-portal protease inhibitor and prostaglandin
might have caused increased coagulation activity in the portal
system.
Table 1. Patient demographics and survival data
No.
Recipient Donor
OutcomesAge/
Gender Etiology
MELD
score ABO
Age/
Gender ABO Relationship
Graft
type
GV
(g)
GV/SLV
(%)
#1 63 F AIH 15 O 32 M A Son Left 650 66.1 Dead1 month
#2 21 F Unknown 19 B 46 M AB Mother Right 520 50.3 Alive 9.1 years
#3 20 F Unknown 17 O 54 M A Father Right 600 48.7 Alive 7.8 years
#4 68 F AIH 27 A 36 M AB Son Left 499 41.6 Alive 1.0 year
#5 51 F AIH 39 O 25 M A Son Left 301 25.1 Alive 10 months
autoimmune hepatitis (AIH), graft volume (GV), high- flow continuous hemodiafiltration (HF-CHDF), intravenous immunoglobulin (IVIG), living
donor liver transplantation (LDLT), model for end stage liver disease (MELD), standard liver volume (SLV)
Table 2. Immunomodulation protocols in ABOi-LDLT
No. Local infusion Rituximab(Pre-LDLT day)
HF-CHDF
(days) Splenectomy
Isoagglutinin titer
before LDLT
Plasma exchange
(Pre-, Post - LDLT)
Basic
immunosuppression
#1 Yes (Portal) - - Yes 128 -32 x2, - Tac, MMF, steroid
#2 Yes (Artery) Yes (-3) - Yes 64 -2 x2, x5 Tac, MMF, steroid
#3 - Yes (-3) - Yes 2048 -64 x6, x5 Tac, MMF, steroid
#4 - Yes (-14) - Yes 32 -32 x19, - CsA, MMF, steroid
#5 - Yes (-15) Yes (11) Yes 512 -128 x13, - Tac MMF, steroid
ABO-incompatible (ABOi), cyclosporine A (CsA), high- flow continuous hemodiafiltration (HF-CHDF), living donor liver transplantation (LDLT),
mycophenolate mofetil (MMF), tacrolimus (Tac)
The Journal of Medical Investigation Vol. 62 August 2015 185
Mycophenolate Mofetil
-14
(Isoagglutinin titer ≤ 128)
Living donor liver transplantation
(+ Splenectomy)
Rituximab
500 mg/body
Tac / CsA
IVIG
0.8 g/kg
(days)
Steroids
-7
High-flow CHDF
Plasma exchange
Case #2 received rituximab 3 days before LDLT and also had
local infusion via the hepatic artery. She underwent re- laparotomy
two times after LDLT for intraabdominal bleeding and hepatic ar-
tery dissection at the catheter tip. She also had AMR on day 7 and
were treated by PEs. Since the initial two cases we abandoned
local infusion treatment for its catheter associated complications.
Thus, the Case #3 received rituximab without having local infu-
sion despite her pre-transplant isoagglutinin titer was very high
(x2048). Although she received PEs after LDLT, she had AMR on
day 4. Her AMR was successfully treated by two session of high-
dose IVIG on day 5 and 10.
Since then, we changed our policy in ABOi-LDLT again, and
planned to put rituximab 2 weeks before LDLT and apply HF-
CHDF to keep a patient away from brain death due to hepatic
coma. Because the Case #4 did not have rapid progressive en-
cephalopathy, she did not received HF-CHDF and underwent
scheduled LDLT 2 weeks after having rituximab. On the other
hand, Case #5 started to have grade II encephalopathy when she
received rituximab, and therefore she was on HF-CHDF for 11
days before LDLT. The last two cases had fairly good post- trans-
plant course.
Graft outcomes
The isoagglutinin titer after LDLT showed rebound elevation in
the Case #2 and #3, both of which received rituximab within a week
before LDLT, with deteriorating liver function tests indicating
AMR. In both cases, CD-20 positive lymphocyte number was zero
after LDLT despite their clinical AMR. Nevertheless, their AMR
episodes were successfully treated by PE with or without IVIG.
Graft was lost only in the Case #1, and therefore graft survival
rate was 80% with good graft function over 3.83.7 years.
DISCUSSION
Because there has been a very limited chance to perform liver
transplantation from deceased donors in Japan, the use of ABOi
donors are often required in LDLT (3-5). Thus, various methods
have been implemented to allow these procedures, including local
infusion (9). The theoretical basis of local administration of pro-
tease inhibitors, prostaglandin, and steroids is that the pathologi-
cal findings of the failed ABOi liver graft show the features of he-
patic disseminated intravascular coagulation (9). Although local
infusion is a theoretically reasonable treatment of choice, there are
problems associated with its application via the portal vein or he-
patic artery includes catheter -related complications, and possible
re- laparotomy for the removal of the catheters (10-12).
Rituximab, an anti -CD20 antibody, is a monoclonal antibody
that specifically targets the CD20 surface antigen expressed on-
B lymphocytes, thus resulting in cell lyses. In the current series,
the Case #3 and #4 were given Rituximab just 3 days before LDLT,
and had rebound elevation of isoagglutinin titers with clinical AMR.
Usui et al. (4) reported on its use as long as 3 weeks before the
LDLT with successful outcomes. Egawa et al. (12) has reported
that administration of rituximab earlier than 7 days before LDLT
significantly depleted B- and memory B-lymphocytes. However in
treating the patients with ALF, LDLT needs to be timely performed
before they encounter advanced stages in hepatic encephalopathy
and brain death due to their anhepatic state.
HF-CHDF uses much more volumes of buffer as much as 200 L
per session and it efficiently removes more low and middle molecu-
lar weight toxic substances (6, 13, 14). Yokoi, et al. (6) compared
the clinical efficacy of HF-CHDF for treating patients with those
of conventional treatments without HF-CHDF, and found that rate
of recovery from coma was significantly higher in the HF-CHDF
group (70.2%) than in the non-HFCHDF group (44.2%). The wider
application of HF-CHDF has changed our strategies in applying
ABOi-LDLT for ALF, because it inhibit the deterioration of hepatic
encephalopathy and reserve days for plasma cells to be disappeared
before emergent LDLT (15). Nevertheless, we think that IVIG is
the last hope of treatment if encephalopathy were not controlled
even by HF-CHDF and emergent LDLT could not be avoided (5).
IVIG might also be the significant factor in ABOi-LDLT. The
proposed mechanisms of action of IVIG on the humoral reaction in-
clude B-cell apoptosis through the Fc-receptor dependent pathway,
and the inhibition of alloreactive T-cell mediated or complement-
mediated allograft injury, although these possibilities have not been
confirmed (16-18). The use of IVIG for induction therapy in ABOi
liver transplantation has never been reported before, although a
limited number of case reports have suggested the use of IVIG for
severe AMR after ABOi LDLT (19). IVIG might have worked on
for these B-lymphocytes, preventing AMR. In a deceased donor
liver transplantation setting using ABOi donors, Urbani et al. (20)
reported very favorable outcomes with the use of IVIG combined
with plasma exchange and extracorporeal photopheresis.
The strategies for safer use of ABOi-LDLT grafts have been
changes over years with refinements. Now our basic policy is ri-
tuximab given 2 weeks before LDLT for ALF, and HF-CHDF is
applied to prevent deterioration of hepatic encephalopathy and
brain death before LDLT. However if advance of encephalopathy
could not be controlled by HF-CHDF, emergent LDLT should be
performed and high-dose IVIG could be applied as a prophylaxis
for AMR (Figure 1).
In conclusion, refinements and revisions in ABOi-LDLT were
performed over fourteen years of experiences, and currently rituxi-
mab-based ABOi-LDLT under HF-CHDF is our choice for treat-
ing deteriorating patients with ALF
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